Lee Hooks, MBA
Chief Executive Officer
Mr. Hooks was appointed Chief Executive Officer of Axio Research Corporation in 2001. He is the former CEO of Point of CareWare.com, a Bellevue-based medical software company. Prior to his position at Point of CareWare.com, Mr. Hooks was Executive Director of Providence Health Plan of Washington. He came to Seattle from San Francisco, where he was Vice President of CSC Index, responsible for this management consulting firm’s West Coast healthcare practice. He received his MBA from the University of Chicago.
Jon Case, MBA
Director of Business Development
Mr. Case is Director of Business Development for Axio Research, LLC. Appointed to this role in 1998, he leads the Axio sales team, develops and guides corporate business strategy, and provides corporate leadership as a member of the Axio Management Team. Additionally, he served as interim CEO of Axio from 2000-2001. Axio Research is the world leader in planning and managing Data Monitoring Committees; Mr. Case leverages his extensive experience and industry contacts in the Biotechnology and Pharmaceutical industry to assist Axio clients in this area. Additionally, he assists clients in the creation of data management teams, clinical events committees, and medical writing groups. Prior to joining Axio, he served as Director of Corporate Development for both Koronis Pharmaceuticals and Targeted Genetics Corporation (now AmpliPhi Biosciences Corporation), both biotechnology companies located in Seattle. Mr. Case also served as Director of Business Development for Centocor, Inc. (now Janssen Biotech, Inc.). He received his BS and MBA from the Wharton School of the University of Pennsylvania.
Michael Antinore, PhD
Director of Business Development (West Coast)
Image Coming Soon
Dr. Michael Antinore joined Axio Research in 2013. He has taken a lead role in business development for Axio’s Biostatistics department as well as all of data management and the statistical genetics departments. Dr. Antinore was appointed Director, Business Development (West Coast) in 2015, being a major contributor on developing long-range strategic plans for the company as well as pivotal corporate decisions bringing rise to Axio’s exponential growth in recent years. Previous to Axio, he managed Business development for Nanogen (now Epoch Biosciences). He received his PhD from University of Rochester and MBA from University of Utah.
Director of Finance
Ms. Nealy was appointed as Axio’s Director of Finance in 2016 after serving as Financial Controller since 2008. She brings close to two decades of accounting, IT, and HR experience to the firm. At Axio, Ms. Nealy oversees financial accounting and project information systems. Prior to joining Axio, she spent eight years in the financial services sector with Seattle private equity firm Montlake Capital, serving as controller for the last five years. Her other professional experiences include positions within the manufacturing and construction industries, including assistant business manager, personnel administrator, staff accountant, and office manager. Ms. Nealy holds a BA in Arts and Sciences from the University of Washington.
Director of Human Resources
Currently Axio’s Human Resources Director, Ms. Richard has worked with the company’s Human Resources team since 2001. She has 20 years of experience in all aspects of Human Resources issues and development in both the consulting and biotech industries. She has served on the Washington Biotechnology & Biomedical Association’s (WBBA) Human Resources Group since 2001. Ms. Richard holds a BA in Business and received her national certification as a Professional in Human Resources (PHR) from the Human Resources Certification Institute.
Director of Information Technology
Mr. Ingersoll joined Axio Research in 2000 and was appointed Project Director in 2002 and Director of Information Technology in 2004. Mr. Ingersoll has more than a dozen years of clinical trial experience, primarily focused on data management, development of custom data collection software, and information technology. In addition, he has directed and managed the data collection for clinical drug and/or device trials as well as numerous QI and PRO projects. These projects range from small, regional Phase 1/2 studies to large, complex, multinational Phase 2/3 studies. Mr. Ingersoll holds a BS in Microbiology from the University of Washington.